Bringing Immunotherapies to Ontario

Bringing Immunotherapies to Ontario Panel

Using genetic engineering, immunotherapies mobilize the body’s own cells against cancer. This revolutionary therapy has demonstrated remarkable curative potential, but comes with a big price tag and many complex technical challenges. Health-care providers, governments and industry are working on solutions that will make this therapy widely available. With the first immunotherapies having won regulatory approval in the United States, we are slowly making progress. What does this mean for Canada? What are the key challenges we need to address to bring immunotherapy to patients here at home?

The discussion included:
– Michael May, PhD, President & CEO, CCRM (Moderator) 
– Donna Wall, MD, Section Head – Blood and Marrow Transplant/Cell Therapy Program, Division of Haematology/Oncology, The Hospital for Sick Children
– Justin Shakespeare, Executive Director, Oncology Business Unit, Amgen 
– Patrick Bedford, Senior Manager, Clinical Translation and Regulatory Affairs, CCRM
– Aaron Dulgar-Tulloch, PhD, Director of BridGE, GE Healthcare Cell Therapy

This event took place during Toronto Health Innovation Week 2018, on April 11, 2018.

CCRM Sits Down With Janet Rossant SickKids Research Institute

CCRM Sits Down With Janet Rossant

Dr. Janet Rossant, SickKids Research Institute, sits down with CCRM and shares her views on the current trends in regenerative medicine and how the potential for commercialization should factor into research plans. Dr. Rossant touches on her research for Cystic Fibrosis and on the changing culture in academia and the need to consider the clinical applications of research. She then explains how new discoveries can be turned into commercial products with the help of organizations like CCRM and the recently established Ontario Institute for Regenerative Medicine (OIRM).

All other pages contact

For more information, please contact us.
Font Resize
Enable Contrast